Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools


You are here: Home / Members / Joel E. Tepper
Joel E. Tepper

Joel E. Tepper

  • M.D.
  • Clinical Research
  • Gastrointestinal Oncology Program
  • Bone and Soft Tissue Oncology Program

  • Radiation Oncology
  • UNC-Chapel Hill
  • 919-445-5216
  • NC Cancer Hospital
  • Link to CV or NIH biosketch

Area of Interest

Primary research emphasis has been on the use of combined modality therapy with radiation therapy, surgery and chemotherapy in gastrointestinal cancers. This includes work evaluating the basic mechanism of interactions between radiation and chemotherapeutic agents as well as evaluating these interactions through clinical trials. In addition, continuing work on the use of new image display techniques in radiation therapy.

Awards and Honors

American Society of Clinical Oncology- Board of Directors,
UNC- Berryhill Lecturer
Past-President and Past-Chairman of the Board- American Society for Therapeutic Radiology and Oncology (ASTRO)

Gold Medal- ASTRO

Steering Committee- ASCO/ASTRO/AGA/SSO GI Oncology Conference

Principle Investigator- UNC GI SPORE (Specialized Program of Research Excellence)

Course co-Director- AACR/ASCO Vail Workshop on Clinical Trials

Co-chair- US GI Intergroup (GI Steering Comm)

Co-PI on a GI Intergroup trial of adjuvant chemoradiation therapy in gastric cancer

Paper demonstrating the value of surgical salvage in rectal cancer in a large Intergroup clinical trial cohort- to be published in the Journal of Clinical Oncology

Demonstration of the importance of substaging of rectal cancer for individualization of adjuvant therapy

Early phase studies defining the ability to combine various agents (farnesyl transferase inhibitors, gemcitabine, oxaliplatin) with radiation therapy in various tumor types

Design of new radiation parameters for adjuvant treatment of gastric cancer and its implementation in the new Intergroup gastric adjuvant trial